Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MacroGenics ( (MGNX) ) has provided an announcement.
On May 1, 2026, MacroGenics entered into a first amendment to its ZYNYZ royalty purchase agreement with Sagard Healthcare Partners, expanding a June 2025 deal under which it sold royalty rights on global net sales of the PD‑1 inhibitor licensed to Incyte. The amendment brings MacroGenics’ aggregate proceeds from Sagard to $130 million while leaving intact the company’s rights to potential development, regulatory and commercial milestones tied to ZYNYZ.
Under the revised structure, Sagard made an additional $60 million cash payment and may pay MacroGenics up to $20 million in a one‑time 2026 sales‑based milestone, after which Sagard’s capped royalty interest will end once it has received 1.7 times its total investment by September 30, 2032, or 2.0 times thereafter. The arrangement provides MacroGenics with non‑dilutive funding while preserving long‑term upside if ZYNYZ sales expand, potentially strengthening the company’s financial flexibility for oncology pipeline development and reinforcing its positioning within the antibody‑based cancer therapeutics space.
The most recent analyst rating on (MGNX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.
Spark’s Take on MGNX Stock
According to Spark, TipRanks’ AI Analyst, MGNX is a Neutral.
The score is held back primarily by weak financial performance, driven by persistent losses, significant cash burn, and declining equity. Technicals are a meaningful offset with a clear upward trend and positive momentum indicators. Valuation remains challenging due to unprofitability, while corporate events are mixed given the trial hold lift alongside notable safety-related regulatory risk.
To see Spark’s full report on MGNX stock, click here.
More about MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company builds its pipeline from proprietary next‑generation antibody platforms and has entered multiple strategic collaborations with global pharmaceutical and biotechnology partners.
ZYNYZ (retifanlimab) is a humanized monoclonal antibody targeting PD‑1, indicated in combination with platinum-based chemotherapy for first‑line treatment of inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal in major markets, and as monotherapy for certain squamous cell carcinoma of the anal canal and Merkel cell carcinoma indications. ZYNYZ is marketed by Incyte in the U.S. under an exclusive global collaboration and license agreement with MacroGenics.
Average Trading Volume: 1,013,465
Technical Sentiment Signal: Buy
Current Market Cap: $198.9M
See more insights into MGNX stock on TipRanks’ Stock Analysis page.